Literature DB >> 30999385

Hyperglycemia and T Cell infiltration are associated with stromal and epithelial prostatic hyperplasia in the nonobese diabetic mouse.

LaTayia M Aaron-Brooks1,2, Takeshi Sasaki2, Renee E Vickman2, Lin Wei3, Omar E Franco2, Yuan Ji3, Susan E Crawford2, Simon W Hayward2.   

Abstract

BACKGROUND: Prostatic inflammation and various proinflammatory systemic comorbidities, such as diabetes and obesity are associated with human benign prostatic hyperplasia (BPH). There is a paucity of in vivo models reflecting specific aspects of BPH pathogenesis. Our aim was to investigate the nonobese diabetic (NOD) mouse as a potential model for subsequent intervention studies.
MATERIALS AND METHODS: We used the NOD mouse, a model of autoimmune inflammation leading to type 1 diabetes to examine the effects of systemic inflammation and diabetes on the prostate. We assessed changes in prostatic histology, infiltrating leukocytes, and gene expression associated with aging and diabetic status.
RESULTS: Both stromal expansion and epithelial hyperplasia were observed in the prostates. Regardless of diabetic status, the degree of prostatic hyperplasia varied. Local inflammation was associated with a more severe prostatic phenotype in both diabetic and nondiabetic mice. Testicular atrophy was noted in diabetic mice, but prostate glands showed persistent focal cell proliferation. In addition, a prostatic intraepithelial neoplasia (PIN)-like phenotype was seen in several diabetic animals with an associated increase in c-Myc and MMP-2 expression. To examine changes in gene and cytokine expression we performed microarray and cytokine array analysis comparing the prostates of diabetic and nondiabetic animals. Microarray analysis revealed several differentially expressed genes including CCL3, CCL12, and TNFS10. Cytokine array analysis revealed increased expression of cytokines and proteases such as LDLR, IL28 A/B, and MMP-2 in diabetic mice.
CONCLUSION: Overall, NOD mice provide a model to examine the effects of hyperglycemia and chronic inflammation on the prostate, demonstrating relevance to some of the mechanisms present underlying BPH and potentially the initiation of prostate cancer.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  animal model of benign prostatic hyperplasia; benign prostatic hyperplasia; nonobese diabetic mice

Mesh:

Substances:

Year:  2019        PMID: 30999385      PMCID: PMC6591734          DOI: 10.1002/pros.23809

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  83 in total

1.  The NOD mouse model of type 1 diabetes: as good as it gets?

Authors:  M A Atkinson; E H Leiter
Journal:  Nat Med       Date:  1999-06       Impact factor: 53.440

2.  A framework for oligonucleotide microarray preprocessing.

Authors:  Benilton S Carvalho; Rafael A Irizarry
Journal:  Bioinformatics       Date:  2010-08-05       Impact factor: 6.937

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

4.  Tissue factor expression and prognosis in patients with metastatic prostate cancer.

Authors:  Takuya Akashi; Yuzo Furuya; Shoichiro Ohta; Hideki Fuse
Journal:  Urology       Date:  2003-12       Impact factor: 2.649

5.  Immunologic aspects of the nonobese diabetic (NOD) mouse. Abnormalities of cellular immunity.

Authors:  S Kataoka; J Satoh; H Fujiya; T Toyota; R Suzuki; K Itoh; K Kumagai
Journal:  Diabetes       Date:  1983-03       Impact factor: 9.461

6.  Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer.

Authors:  L Zhang; J Shi; J Feng; H Klocker; C Lee; J Zhang
Journal:  Prostate Cancer Prostatic Dis       Date:  2004       Impact factor: 5.554

7.  Non-obese diabetic (NOD) mice are genetically susceptible to experimental autoimmune prostatitis (EAP).

Authors:  V E Rivero; C Cailleau; M Depiante-Depaoli; C M Riera; C Carnaud
Journal:  J Autoimmun       Date:  1998-12       Impact factor: 7.094

8.  Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia.

Authors:  J Hammarsten; B Högstedt; N Holthuis; D Mellström
Journal:  Prostate Cancer Prostatic Dis       Date:  1998-03       Impact factor: 5.554

9.  Testosterone and 17β-estradiol induce glandular prostatic growth, bladder outlet obstruction, and voiding dysfunction in male mice.

Authors:  Tristan M Nicholson; Emily A Ricke; Paul C Marker; Joseph M Miano; Robert D Mayer; Barry G Timms; Frederick S vom Saal; Ronald W Wood; William A Ricke
Journal:  Endocrinology       Date:  2012-09-04       Impact factor: 4.736

10.  Lipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity.

Authors:  Guanxiong Ding; Jianqing Wang; Chenchen Feng; Haowen Jiang; Jianfeng Xu; Qiang Ding
Journal:  Oncotarget       Date:  2016-09-27
View more
  6 in total

1.  Obesity-associated inflammation induces androgenic to estrogenic switch in the prostate gland.

Authors:  Bichen Xue; Shulin Wu; Christina Sharkey; Shahin Tabatabaei; Chin-Lee Wu; Zhipeng Tao; Zhiyong Cheng; Douglas Strand; Aria F Olumi; Zongwei Wang
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-02-06       Impact factor: 5.554

Review 2.  Animal models of benign prostatic hyperplasia.

Authors:  Junjie Zhang; Mengda Zhang; Jin Tang; Guangming Yin; Zhi Long; Leye He; Chuanchi Zhou; Lufeng Luo; Lin Qi; Long Wang
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-09-01       Impact factor: 5.554

Review 3.  Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review.

Authors:  Abdolreza Haghpanah; Fatemeh Masjedi; Mehdi Salehipour; Alireza Hosseinpour; Jamshid Roozbeh; Anahita Dehghani
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-05-18       Impact factor: 5.455

4.  Construction of Potential Gene Expression and Regulation Networks in Prostate Cancer Using Bioinformatics Tools.

Authors:  Heyu Liu; Lirong Li; Yuan Fan; Yaping Lu; Changhong Zhu; Wei Xia
Journal:  Oxid Med Cell Longev       Date:  2021-08-31       Impact factor: 6.543

5.  TNF is a potential therapeutic target to suppress prostatic inflammation and hyperplasia in autoimmune disease.

Authors:  Renee E Vickman; LaTayia Aaron-Brooks; Renyuan Zhang; Nadia A Lanman; Brittany Lapin; Victoria Gil; Max Greenberg; Takeshi Sasaki; Gregory M Cresswell; Meaghan M Broman; J Sebastian Paez; Jacqueline Petkewicz; Pooja Talaty; Brian T Helfand; Alexander P Glaser; Chi-Hsiung Wang; Omar E Franco; Timothy L Ratliff; Kent L Nastiuk; Susan E Crawford; Simon W Hayward
Journal:  Nat Commun       Date:  2022-04-19       Impact factor: 17.694

6.  Integrative Analyses of Genes Associated with Fulminant Type 1 Diabetes.

Authors:  Xiaofeng Ye; Tianshu Zeng; Wen Kong; Lu-Lu Chen
Journal:  J Immunol Res       Date:  2020-10-06       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.